Zoliflodacin

Alias: Zoliflodacin; ETX0914; AZD-0914; ETX-0914; AZD0914; ETX 0914; AZD 0914
Cat No.:V4277 Purity: =98.88%
Zoliflodacin (formerly ETX-0914; AZD-0914; ETX0914; AZD0914) is a novel and potent spiropyrimidinetrione-based bacterial DNA gyrase/topoisomerase inhibitor.
Zoliflodacin Chemical Structure CAS No.: 1620458-09-4
Product category: DNA(RNA) Synthesis
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
500μg
1mg
5mg
10mg
25mg
50mg
100mg
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
InvivoChem's Zoliflodacin has been cited by 1 publication
Purity & Quality Control Documentation

Purity: =98.88%

Product Description

Zoliflodacin (formerly ETX-0914; AZD-0914; ETX0914; AZD0914) is a novel and potent spiropyrimidinetrione-based bacterial DNA gyrase/topoisomerase inhibitor. Zoliflodacin exhibits strong in vitro antibacterial activity against both Gram-positive and Gram-negative bacteria, including S. aureus with the MIC90 of 0.25 μg/mL. With regard to important Gram-positive (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, and Streptococcus agalactiae), fastidious Gram-negative (Haemophilus influenzae and Neisseria gonorrhoeae), atypical (Legionella pneumophila), and anaerobic (Clostridium difficile) bacterial species, including isolates with documented fluoroquinolone resistance, AZD0914 exhibits strong in vitro antibacterial activity. In contrast to other commercially available antibacterial compounds, AZD0914 inhibits DNA biosynthesis and the accumulation of double-strand cleavages. Under permissive conditions, AZD0914 stabilizes and arrests the cleaved covalent complex of gyrase with double-strand broken DNA, preventing the double-strand cleaved DNA from religating to form fused circular DNA. This mechanism is different in terms of mechanics even though it is comparable to that of fluoroquinolones. In S. aureus, AZD0914 showed low frequencies of spontaneous resistance; if mutants were obtained, they mapped to gyrB. Furthermore, AZD0914 did not exhibit any cross-resistance against recent clinical isolates of bacteria that were resistant to fluoroquinolones or other drug classes, such as glycopeptides, β-lactams, macrolides, and oxazolidinones. In vitro time-kill studies and minimum bactericidal concentration tests, AZD0914 demonstrated bactericidal activity. Only additivity or indifference was seen in in vitro checkerboard/synergy testing using 17 comparator antibacterials. AZD0914's low frequency of resistance, lack of cross-resistance, strong in vitro antibacterial activity (including activity against isolates resistant to fluoroquinolones), and bactericidal activity all contribute to its continued development.

Biological Activity I Assay Protocols (From Reference)
Targets
Quinolone
ln Vitro
Zoliflodacin (formerly ETX-0914; AZD-0914; ETX0914; AZD0914) possesses antibacterial activity against important fastidious Gram-negative (Haemophilus influenzae, Neisseria gonorrhoeae), atypical (Legionella pneumophila), anaerobic (Clostridium difficile), and Gram-positive (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, and Streptococcus agalactiae), fastidious Gram-negative (Haemophilus influenzae, Neisseria gonorrhoeae), and atypical (Legionella pneumophila) bacterial species, including isolates with documented fluoroquinolone resistance. The mechanism of action of Zoliflodacin is demonstrated to be different from that of other commercially available antibacterial compounds, such as fluoroquinolones, in that it inhibits DNA biosynthesis and accumulates double-strand cleavages, thereby exerting antibacterial activity. Under permissive conditions, zoliflodacin stabilizes and arrests the cleaved covalent complex of gyrase with double-strand broken DNA, preventing the double-strand cleaved DNA from religating to form fused circular DNA[1].
Cell Assay
The determination of the macrodilution MICs for zoliflodacin broth serves as the foundation for in vitro time-kill and postantibiotic-effect (PAE) assays. Using glass tubes (18 by 150 mm, without agitation), in vitro static time-kill studies are carried out with 10-mL volumes of cation-adjusted Mueller-Hinton broth containing logarithmically growing cultures (starting inoculum of 1×106 CFU/mL) against both levofloxacin-susceptible and levofloxacin-resistant S. aureus. The concentrations of zoliflodacin that are tested are 0.5, 1, 2, 4, and 8 times the minimum inhibitory concentration (MIC). Samples are plated for colony counts at 0, 2, 4, 6, 8, and 24 hours using 100 μL aliquots spotted onto 25-ml sheep blood agar plates according to the previously mentioned protocol. At the lowest drug concentration that decreased viable organism counts by ≥3 log10 in a 24-hour period, compounds are deemed bactericidal. Time-kill research is carried out in duplicate, with test results combined and mean values reported [1].
References

[1]. In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria. Antimicrob Agents Chemother. 2015 Jan;59(1):467-74.

These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C22H22N5O7F
Molecular Weight
487.438
Exact Mass
487.15
Elemental Analysis
C, 54.21; H, 4.55; F, 3.90; N, 14.37; O, 22.98
CAS #
1620458-09-4
Appearance
Solid powder
SMILES
C[C@@H]1CN2[C@H]([C@@H](O1)C)C3(CC4=CC5=C(C(=C42)F)ON=C5N6[C@H](COC6=O)C)C(=O)NC(=O)NC3=O
InChi Key
ZSWMIFNWDQEXDT-ZESJGQACSA-N
InChi Code
InChI=1S/C22H22FN5O7/c1-8-7-33-21(32)28(8)17-12-4-11-5-22(18(29)24-20(31)25-19(22)30)16-10(3)34-9(2)6-27(16)14(11)13(23)15(12)35-26-17/h4,8-10,16H,5-7H2,1-3H3,(H2,24,25,29,30,31)/t8-,9+,10-,16+/m0/s1
Chemical Name
(4'R,6'S,7'S)-17'-fluoro-4',6'-dimethyl-13'-[(4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]spiro[1,3-diazinane-5,8'-5,15-dioxa-2,14-diazatetracyclo[8.7.0.02,7.012,16]heptadeca-1(17),10,12(16),13-tetraene]-2,4,6-trione
Synonyms
Zoliflodacin; ETX0914; AZD-0914; ETX-0914; AZD0914; ETX 0914; AZD 0914
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~140 mg/mL (~287.2 mM)
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.27 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.08 mg/mL (4.27 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

View More

Solubility in Formulation 3: ≥ 2.08 mg/mL (4.27 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.


 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.0515 mL 10.2577 mL 20.5153 mL
5 mM 0.4103 mL 2.0515 mL 4.1031 mL
10 mM 0.2052 mL 1.0258 mL 2.0515 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03959527 Active
Recruiting
Drug: zoliflodacin
Drug: ceftriaxone
Gonorrhea Global Antibiotics Research
and Development Partnership
November 6, 2019 Phase 3
NCT03404167 Completed Drug: AZD0914 Gonorrhoea National Institute of Allergy
and Infectious Diseases (NIAID)
February 2, 2018 Phase 1
NCT03718806 Completed Other: high calorie, high fat
breakfast
Drug: Zoliflodacin
Gonorrhea Drugs for Neglected Diseases October 3, 2018 Phase 1
NCT05635305 Completed Drug: Zoliflodacin Patheon Healthy Volunteers Global Antibiotics Research
and Development Partnership
November 9, 2022 Phase 1
NCT02257918 Completed Drug: AZD0914
Drug: Ceftriaxone
Gonorrhoea National Institute of Allergy
and Infectious Diseases (NIAID)
November 25, 2014 Phase 2
Biological Data
Contact Us Back to top